Elicio Therapeutics Statistics
Elicio Therapeutics (9HA) Stock Statistics & Valuation Metrics
Total Valuation
Elicio Therapeutics has a market cap or net worth of EUR 40.81M. The enterprise value is EUR 30.94M.
- Market Cap
- EUR 40.81M
- Enterprise Value
- EUR 30.94M
Share Statistics
Elicio Therapeutics has 28,307,224 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 28,307,224
- Owned by Insiders
- 20.59%
- Owned by Institutions
- 12.35%
Financial Efficiency
Elicio Therapeutics’s return on equity (ROE) is -24.19 and return on invested capital (ROIC) is -201.00%.
- Return on Equity (ROE)
- -24.19
- Return on Assets (ROA)
- -1.53
- Return on Invested Capital (ROIC)
- -201.00%
- Return on Capital Employed (ROCE)
- -2.12
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.20M
- Employee Count
- 33
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Elicio Therapeutics is -0.88. Elicio Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -0.88
- PS Ratio
- 0.00
- PB Ratio
- 2.25
- Price to FCF
- -0.83
- Price to Operating Cash Flow
- -1.14
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Elicio Therapeutics had revenue of 0 and earned -39.57M in profits. Earnings per share was -2.58.
- Revenue
- 0
- Gross Profit
- -1.13M
- Operating Income
- -37.71M
- Pretax Income
- -39.57M
- Net Income
- -39.57M
- EBITDA
- -37.31M
- Earnings Per Share (EPS)
- -2.58
Cash Flow
In the last 12 months, operating cash flow was -36.97M and capital expenditures -16,000, giving a free cash flow of -36.99M billion.
- Operating Cash Flow
- -36.97M
- Free Cash Flow
- -36.99M
- Free Cash Flow per Share
- -1.41
Dividends & Yields
Elicio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -110.54%
- Earnings Yield
- -77.45%
Stock Price Statistics
- Beta
- -0.60
- 52-Week Price Change
- -80.27%
- 50-Day Moving Average
- 1.67
- 200-Day Moving Average
- 5.65
- Relative Strength Index (RSI)
- 39.78
- Average Volume (3m)
- 435
Important Dates
Elicio Therapeutics upcoming earnings date is Mar 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Elicio Therapeutics as a current ratio of 2.38, with Debt / Equity ratio of 887.04%
- Current Ratio
- 2.38
- Quick Ratio
- 2.38
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- 0.11
- Interest Coverage Ratio
- -33.29
Taxes
In the past 12 months, Elicio Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Elicio Therapeutics EV to EBITDA ratio is -0.24, with an EV/FCF ratio of -0.25.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.24
- EV to Free Cash Flow
- -0.25
- EV to Operating Cash Flow
- -0.25
Balance Sheet
Elicio Therapeutics has EUR 30.90M in cash and marketable securities with EUR 6.83M in debt, giving a net cash position of EUR 24.07M billion.
- Cash & Marketable Securities
- EUR 30.90M
- Total Debt
- EUR 6.83M
- Net Cash
- EUR 24.07M
- Net Cash Per Share
- EUR 0.85
- Tangible Book Value Per Share
- EUR 0.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Elicio Therapeutics is EUR 12.92, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 12.92
- Price Target Upside
- 778.92% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 49.89%
Scores
- Smart Score
- 1
- AI Score
- ―
